Clinical Data Maze tumbles despite positive data for kidney disease drug BioPharma DiveInvestors had reservations about data for a drug that could compete with a candidate from Vertex in APOL1-mediated kidney disease.Clinical DataRare DiseaseRead full story pharminent March 25, 2026 (Last updated: March 26, 2026) BioPharma Dive Investors had reservations about data for a drug that could compete with a candidate from Vertex in APOL1-mediated kidney disease. Clinical DataRare DiseaseRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Beam posts positive data on base editing treatment for AATDNext: Wave crashes on obesity drug update; Kodiak’s reboot pays dividends Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
